Shares of Nuformix plc (LON:NFX – Get Free Report) reached a new 52-week low on Thursday. The stock traded as low as GBX 0.12 and last traded at GBX 0.12, with a volume of 52582754 shares traded. The stock had previously closed at GBX 0.14.
Nuformix Trading Down 11.1%
The stock has a market capitalization of £3.13 million, a PE ratio of -4.10 and a beta of 1.53. The firm has a 50-day moving average price of GBX 0.15 and a 200-day moving average price of GBX 0.17.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Further Reading
- Five stocks we like better than Nuformix
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
- This Space ETF Offers SpaceX Exposure—But Investors Are Paying for the Volatilit
- Does Lemonade’s Growth Signal Profits Ahead?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
